---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-045022"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:11:01.225054+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbCellera Q3 net loss widens to $51.1M as expenses rise; revenue flat at $6.5M

## Summary
- Revenue $6.5M, flat QoQ and YoY; net loss $51.1M ($0.17/share) vs $28.6M ($0.10/share) in Q3 2023.
- R&D expenses rose to $41.0M from $37.9M; G&A expenses increased to $19.1M from $14.4M.
- Cumulative partner programs with downstreams reached 95 (up 13% YoY); molecules in clinic grew to 14 from 10.
- Expanded Lilly collaboration into immunology, cardiovascular, neuroscience; completed Vancouver HQ consolidation.
- Total liquidity over $875M ($670M cash + $205M government funding).

## SEC filing metadata
- accession: 0001628280-24-045022
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000162828024045022/0001628280-24-045022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000162828024045022/abcl-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-045022
- JSON: https://secwatch.observer/filing/0001628280-24-045022.json
- Plain text: https://secwatch.observer/filing/0001628280-24-045022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.